Diabetic Gastroparesis therapeutic pipeline analysis is expected to grow as observed by the current situation of increasing prevalence of diabetes, globally. Major factors driving the pipeline analysis for diabetic gastroparesis include obesity, incidence of diabetes mellitus, stress conditions and gastroesophageal reflux disease. As there are very limited number of companies are making an analog for treatment and increasing awareness about health issues are driving the pipeline growth of diabetic gastroparesis. In the U.S., approximately six million people suffer from diabetic gastroparesis or idiopathic gastroparesis.
Diabetes gastroparesis is a long-term complication of diabetes which usually occurs due to prolonged increased blood sugar level. This led to the damaging of nerves in many parts of the body including vagus nerve. The most common causes of diabetic gastroparesis are diabetes mellitus, gastroesophageal reflux disease, functional dyspepsia and postsurgical delayed gastric emptying. Although, there is an increasing prevalence of delayed gastric emptying the when measured scintigraphically, and it usually occurs in patients with functional dyspepsia. Some of the most common symptoms of diabetic gastroparesis are post-prandial fullness, which generally become life threatening because there is imbalance in electrolyte and nutrition. Patient suffering from frequent vomiting in very large volume for many hours is a strong symptom of gastroparesis. Gastric emptying is now become common because it can happen due to most of the gastrointestinal disorder.
Most of the drugs that are in the clinical trials, have provided promising results of treating or reducing the incidence of diabetic gastroparesis. TZP-102, in Phase II is a novel, potent and ghrelin receptor agonist.
Most of the trials conducted in the past for the treatment of diabetic gastroparesis have failed. Ironwood Pharmaceuticals, Inc. developed compound IW-9179 which had not shown promising results and not reduced the symptoms of patients with diabetic gastroparesis. TZP-102, developed by Tranzyme, Inc. have also showed failure in diabetic gastroparesis. Motus Therapeutics, Inc. is currently developing peptide, relamorelin, for the treatment of dibetic gastroparesis and is in Phase II clinical trials. It is identified as a ghrelin agonist. GlaxoSmithKline plc is also introducing compound GSK962040, motilin receptor agonist, showing promising results in Phase II clinical trials. Recently Theravance Biopharma, Inc. received FDA approval for TD-5108 (Velusetrag) for diabetic gastroparesis which is an oral investigational drug, which has shown agonistic activity against human 5-HT4 receptor. 5-HT4 receptor agonist are given usually for the treatment of chronic constipation and GI tract dysfunction. In Phase II clinical trials of TD-5108, it was shown that the first three doses of drug helped to reduce the gastric emptying time as compared to placebo in patient with idiopathic or diabetic gastroparesis. Some of the drugs that are being currently marketed include anti-emetics, 5-HT4 receptor agonist and medications to treat gastro-motility disorder.
Various institutes, companies and associations are collaborating for development of drugs for treatment of diabetic gastroparesis. Takeda Pharmaceuticals and Altos Therapeutics entered into an agreement for the development of compound ATC-1906 for the treatment of gastroparesis and its symptoms. ATC-1906 is an oral dopamine D2/D3 receptor antagonist given for vomiting in patients.
Some of the companies having a pipeline of diabetic gastroparesis therapeutics include Evoke Pharma, Inc., GlaxoSmithKline Plc, Cempra, Inc., Ironwood Pharmaceuticals, Inc., Shire Plc, Rhythm Pharmaceuticals, Inc. and Theravance Biopharma, Inc.